THYROID CANCERS

Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.

In a study performed at MD Anderson Cancer Center, there was no significant overall survival impact in patients with anaplastic thyroid cancer who had prior differentiated thyroid cancer, concomitant differentiated thyroid cancer, and prior non thyroid cancers.

Yuri E. Nikiforov, MD, PhD, discusses the reclassification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which has significantly influenced the thyroid cancer space.

In an interview with Targeted Oncology, Yuri E. Nikiforov, MD, PhD, discussed what led to the reclassification of NIFTP and the incidence of thyroid cancer in patients.

In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.

During a Targeted Oncology™ Case-Based Roundtable™ event, Marcia S. Brose, MD, PhD, discussed the case of a patient with advanced thyroid cancer who was previously treated with radioactive iodine and has an NTRK fusion alteration.

Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the importance of long-term survivorship care and its correlation with quality-of-life in patients with thyroid cancer.

In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.

In an interview with Targeted Oncology, Melanie Goldfarb, MD, MSc, FACS, FACE, highlighted the importance of long-term survivorship care and the quality-of-life aspects of patients with thyroid cancer.

Dr Lori Wirth highlights remaining unmet needs and challenges in the treatment of advanced RAI-R-DTC.

Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.

Lori Wirth, MD, explains what regimen is considered to be the standard-of-care treatment for patients with advanced RAI-R-DTC.

Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.

Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.

Lori Wirth, MD, provides an overview of differentiated thyroid cancer (DTC) and radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC).

Melanie Goldfarb, MD, MSc, FACS, FACE, FSSO, discusses the importance of survivorship and providing care to patients with thyroid cancer.

During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.

In an interview with Targeted Oncology™, R. Michael Tuttle, MD, discussed the plethora of treatment options for thyroid cancer as well as overtreatment and undertreatment of the disease.

Advances in thyroid cancer to date hold promise for other orphan cancers with analogous alterations, on which we might bring to bear agents that will have similar effects.

Larisa Greenberg, MD, discusses how the treatment landscape for metastatic thyroid cancer has moved forward in recent years.

In an interview with Targeted Oncology, Megan R. Haymart, MD, provided a recap of a symposium at the American Thyroid 2022 Annual Meeting and discussed disparities in thyroid cancer care, as well as potential solutions

Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.

Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.

A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.

Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.

Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.

Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.

In an interview with Targeted Oncology, Jennifer Hong Kuo, MD, discussed the use of radiofrequency ablation to treat thyroid nodules and how research from Columbia University will guide further research around this topic

Aime T. Franco, PhD, discusses how recent research has explored the difference between pediatric thyroid cancer and adult thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.

An extended follow-up of the phase 3 COSMIC-311 trial supported the use of cabozantinib to treat patients with radioiodine-refractory differentiated thyroid cancer, irrespective of the duration of prior lenvatinib received.